Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Makes A Specialty M&A Play In Deal To Buy Auspex

This article was originally published in The Pink Sheet Daily

Executive Summary

The Israeli generic drug company will gain a lead drug in development for movement disorders, including chorea associated with Huntington’s disease, with the $3.5 billion acquisition of Auspex Pharmaceuticals.

Advertisement

Related Content

Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response
Teva’s Austedo Positioned To Compete With A Generic Rival
Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel